Management of Osteoporosis in Patients Living With HIV-A Systematic Review and Meta-analysis.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 01 2020
01 01 2020
Historique:
entrez:
7
12
2019
pubmed:
7
12
2019
medline:
7
7
2020
Statut:
ppublish
Résumé
Osteoporosis is reported as a common comorbidity in patients living with HIV (PLHIV). The aim of this systematic review and meta-analysis is to assess the evidence on fracture risk in PLHIV, bone mineral density (BMD) in PLHIV compared with controls, longitudinal changes in BMD in PLHIV, and effect of antiosteoporosis treatment in PLHIV. A systematic literature search was conducted using the databases Medline at PubMed and EMBASE using the search terms: "HIV" and "fracture" or "bone turnover," or "bone mineral density." Eligibility criteria followed the aim of the study and include randomized controlled trials and observational studies. Two reviewers extracted the data independently. Meta-analysis was performed using random-effects model assessing fracture risk, BMD compared with controls, and changes in BMD. One hundred forty-two of 2397 papers identified were included in the systematic review, and subsequently, 84 were included in the meta-analysis. The risks of a fragility fracture [1.51, 95% confidence interval (CI): 1.41 to 1.63] and hip fracture (4.05, 95% CI: 2.99 to 5.49) were increased. PLHIV have lower BMD at the hip (z-score -0.31, 95% CI: -0.46 to -0.27) and lumbar spine (z-score -0.36, 95% CI: -0.39 to -0.15) compared with controls. The reduced BMD did not fully explain the increased fracture risk in PLHIV. Current management of osteoporosis in PLHIV follows general osteoporosis guidelines; however, the increased fracture risk is not fully explained by lower BMD, and thus, antiosteoporosis intervention may be beneficial at a higher BMD in PLHIV.
Identifiants
pubmed: 31809356
doi: 10.1097/QAI.0000000000002207
pii: 00126334-202001010-00001
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Références
Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–e356.
Statens Serum Institute. EPI-NYT: Overvågning Og Forebyggelse Af Smitsomme Sygdomme. HIV 2016. 2017. Available at: https://mailchi.mp/ssi/epi-nyt-uge-36-2017-emne-hiv-2016?e=127eacf50f. Accessed July 31, 2018.
Hjalte F, Calara PS, Blaxhult A, et al. Excess costs of non-infectious comorbidities among people living with HIV-estimates from Denmark and Sweden. AIDS Care. 2018;30:1–9.
Moher D, Altman DG, Liberati A, et al. PRISMA statement. Epidemiology. 2011;22:128; author reply 128.
Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128:305–310.
Kelly TJ. Bone mineral density reference databases for American men and women. J.Bone Miner.Metab. 1990;5(suppl1):249.
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–1259.
Prieto-Alhambra D, Guerri-Fernandez R, De Vries F, et al. HIV infection and its association with an excess risk of clinical fractures: a nationwide case-control study. J Acquir Immune Defic Syndr. 2014;66:90–95.
Prior J, Burdge D, Maan E, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int. 2007;18:1345–1353.
Bolland MJ, Grey AB, Horne AM, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92:1283–1288.
Bolland MJ, Grey A, Horne AM, et al. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART). Clin Endocrinol (Oxf). 2012;76:643–648.
Ofotokun I, Titanji K, Lahiri CD, et al. A single-dose zoledronic acid infusion prevents antiretroviral therapy-induced bone loss in treatment-naive HIV-infected patients: a phase IIb trial. Clin Infect Dis. 2016;63:663–671.
Negredo E, Bonjoch A, Pérez-Ãlvarez N, et al. A randomized open label study for comparing two doses of zoledronic acid in HIV infected patients. Top Antivir Med 2014;22:402.
Hoy JF, Richardson R, Ebeling PR, et al. Zoledronic acid is superior to tenofovir DF-switching for low bone mineral density in adults with HIV: a randomised trial. AIDS. 2018;32:1967–1975.
Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015;60:1242–1251.
McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937–946.
Negredo E, Bonjoch A, Clotet B. Management of bone mineral density in HIV-infected patients. Expert Opin Pharmacother. 2016;17:845–852.
EACS. GUIDELINES Version 9.0. 2017. Available at: http://www.eacsociety.org/files/guidelines_9.0-english.pdf. Accessed June 26, 2018.
Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:e1–34.
BHIVA. British HIV Association Guidelines for the Routine Investigation and Monitoring of Adult HIV-1-Positive Individuals 2016. 2016. Available at: http://www.bhiva.org/documents/Guidelines/Monitoring/2016-BHIVA-Monitoring-Guidelines.pdf. Accessed June 26, 2018.
Bolland MJ, Grey A, Reid IR. Skeletal health in adults with HIV infection. Lancet Diabetes Endocrinol. 2015;3:63–74.
Ballane G, Cauley JA, Luckey MM, et al. Worldwide prevalence and incidence of osteoporotic vertebral fractures. Osteoporos Int. 2017;28:1531–1542.
Peters BS, Perry M, Wierzbicki AS, et al. A cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 study. PLoS One. 2013;8:e78048.
Yang J, Sharma A, Shi Q, et al. Improved fracture prediction using different FRAX adjustments in HIV-infected women. AIDS. 2018;32:1699–1706.
Yin MT, Shiau S, Rimland D, et al. Fracture prediction with modified-FRAX in older HIV-infected and uninfected men. J Acquir Immune Defic Syndr. 2016;72:513–520.
Arribas JR, Thompson M, Sax PE, et al. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. J Acquired Immune Defic Syndr. 2017;75:211–218.
Freitas SZ, Teles SA, Lorenzo PC, et al. HIV and HCV coinfection: prevalence, associated factors and genotype characterization in the Midwest region of Brazil. Rev Inst Med Trop Sao Paulo. 2014;56:517–524.
Singh KP, Crane M, Audsley J, et al. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017;31:2035–2052.
Byrne DD, Newcomb CW, Carbonari DM, et al. Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. J Hepatol. 2014;61:210–218.
Hansen AB, Omland LH, Krarup H, et al. Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study. J Hepatol. 2014;61:15–21.
Byrne DD, Newcomb CW, Carbonari DM, et al. Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection. J Viral Hepat. 2015;22:936–947.
Bedimo R, Maalouf NM, Lo Re V III. Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture. Curr Opin HIV AIDS. 2016;11:285–293.
Erlandson KM, Allshouse AA, Jankowski CM, et al. Risk factors for falls in HIV-infected persons. J Acquir Immune Defic Syndr. 2012;61:484–489.
Debroy P, Lake JE, Sim M, et al. Lean mass declines consistently over 10 years in people living with HIV on antiretroviral therapy, with patterns differing by sex. Antivir Ther. 2019.
Erlandson KM, Zhang L, Ng DK, et al. Risk factors for falls, falls with injury, and falls with fracture among older men with or at risk of HIV infection. J Acquir Immune Defic Syndr. 2019;81:e117–e126.
Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93:3499–3504.
Gonciulea A, Wang R, Althoff KN, et al. An increased rate of fracture occurs a decade earlier in HIV+ compared with HIV-men. AIDS. 2017;31:1435–1443.
Guerri-Fernandez R, Molina-Morant D, Villar-Garcia J, et al. Bone density, microarchitecture, and tissue quality after long-term treatment with tenofovir/emtricitabine or abacavir/lamivudine. J Acquir Immune Defic Syndr. 2017;75:322–327.
Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319–1328.
Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48:3224–3229.